445 reports of this reaction
2.5% of all DAPSONE GEL, 5% reports
#3 most reported adverse reaction
PYREXIA is the #3 most commonly reported adverse reaction for DAPSONE GEL, 5%, manufactured by Encube Ethicals, Inc.. There are 445 FDA adverse event reports linking DAPSONE GEL, 5% to PYREXIA. This represents approximately 2.5% of all 17,987 adverse event reports for this drug.
Patients taking DAPSONE GEL, 5% who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is a less commonly reported adverse event for DAPSONE GEL, 5%, but still significant enough to appear in the safety profile.
In addition to pyrexia, the following adverse reactions have been reported for DAPSONE GEL, 5%:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 445 FDA reports for DAPSONE GEL, 5%. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 2.5% of all adverse event reports for DAPSONE GEL, 5%, making it one of the most commonly reported side effect.
If you experience pyrexia while taking DAPSONE GEL, 5%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.